NO972868L - Oligonukleotid-dendrimer konjugater - Google Patents

Oligonukleotid-dendrimer konjugater

Info

Publication number
NO972868L
NO972868L NO972868A NO972868A NO972868L NO 972868 L NO972868 L NO 972868L NO 972868 A NO972868 A NO 972868A NO 972868 A NO972868 A NO 972868A NO 972868 L NO972868 L NO 972868L
Authority
NO
Norway
Prior art keywords
dendrimer
oligonucleotide
natural
modified
nucleic acid
Prior art date
Application number
NO972868A
Other languages
English (en)
Other versions
NO972868D0 (no
Inventor
Robert Haener
Konstantinos Skobridis
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO972868D0 publication Critical patent/NO972868D0/no
Publication of NO972868L publication Critical patent/NO972868L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Oligonukleotid-dendrimer konjugater, der dendrimeren er et enverdig residie av en dendrimer av første til tiende generasjon og oligonukleotidet er en naturlig, modifisert eller syntetisk sekvens som består av naturlige, modifiserte eller syntetiske deoksynukleosider eller peptidnukleinsyrebyggeblokker som er bundet via intemukleotidbroer og som omfatter en region som er komplementær, fortrinnsvis fullstendig komplementær, til en målnukleinsyre (mål-RNA eller mål-DNA), der dendrimeren er bundet til en intemukleotidbro, en nukleinsyrebase eller en sukker av nukleotidet, og saltene av disse.
NO972868A 1994-12-21 1997-06-20 Oligonukleotid-dendrimer konjugater NO972868L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH385494 1994-12-21
CH4795 1995-01-09
PCT/EP1995/004933 WO1996019240A1 (en) 1994-12-21 1995-12-13 Oligonucleotide-dendrimer conjugates

Publications (2)

Publication Number Publication Date
NO972868D0 NO972868D0 (no) 1997-06-20
NO972868L true NO972868L (no) 1997-08-19

Family

ID=25683356

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972868A NO972868L (no) 1994-12-21 1997-06-20 Oligonukleotid-dendrimer konjugater

Country Status (9)

Country Link
EP (1) EP0790837A1 (no)
JP (1) JPH10510822A (no)
AU (1) AU4344696A (no)
CA (1) CA2206915A1 (no)
FI (1) FI972548A (no)
HU (1) HUT77521A (no)
IL (1) IL116456A0 (no)
NO (1) NO972868L (no)
WO (1) WO1996019240A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
IL133087A0 (en) * 1997-05-28 2001-03-19 Nielsen Peter E Conjugated peptide nucleic acids having enhanced cellular uptake
GB9718129D0 (en) 1997-08-27 1997-10-29 Isis Innovation Branched structures
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
FR2906532B1 (fr) 2006-09-28 2008-12-12 Biomerieux Sa Nouvel oligonucleotide marque
FR2933410B1 (fr) 2008-07-04 2010-08-20 Biomerieux Sa Nouvelle sonde de detection
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
CN112898580B (zh) * 2019-12-03 2022-11-08 安序源生物科技(深圳)有限公司 测序试剂
CN112898575B (zh) * 2019-12-03 2022-10-21 深圳清华大学研究院 树杈状大分子修饰的核苷酸的制备方法
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83567A (en) * 1986-08-18 1992-02-16 Dow Chemical Co Starburst conjugates with a carried material,such as an agricultural or pharmaceutical material
IL107715A0 (en) * 1992-11-25 1994-02-27 Baxter Int Water soluble non-immunogenic polyamide cross-linking agents
AU681735C (en) * 1993-07-14 2002-02-21 Regents Of The University Of California, The Self-assembling polynucleotide delivery system comprising dendrimer polycations
ATE277640T1 (de) * 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
IT1270994B (it) * 1994-03-18 1997-05-26 Bracco Spa Macromolecole ramificate a struttura poliossialchilica e loro usi

Also Published As

Publication number Publication date
CA2206915A1 (en) 1996-06-27
NO972868D0 (no) 1997-06-20
FI972548A (fi) 1997-06-23
HUT77521A (hu) 1998-05-28
IL116456A0 (en) 1996-03-31
AU4344696A (en) 1996-07-10
EP0790837A1 (en) 1997-08-27
JPH10510822A (ja) 1998-10-20
WO1996019240A1 (en) 1996-06-27
FI972548A0 (fi) 1997-06-16

Similar Documents

Publication Publication Date Title
NO972868L (no) Oligonukleotid-dendrimer konjugater
BR9808154A (pt) Moléculas de ácido nucléico codificando enzimas tendo atividade de frutosil polimerase
DK51092D0 (da) Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
BR9813968A (pt) Moléculas de ácido nucléico que codificam proteìnas tendo atividade frutosil transferase e processos para produzir inulina de cadeia longa
ES2243007T3 (es) Sintesis quimica completa y sintesis de genes de genomas.
DE69834056D1 (de) De novo oder "universaler" sequenzierungs-array
BR9913878A (pt) Sintases
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
FI972333A0 (fi) Entsymaattiset DNA-molekyylit
DK0408295T3 (da) Fremgangsmåder til opformering af nukleinsyresekvenser
WO1998039485A3 (en) Compositions and methods for analysis of nucleic acids
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DE69524740D1 (de) Thymidin-kinase-mutanten
CY1109797T1 (el) Μορια πυρηνικου οξεος, κωδικοποιουντα ενζυμα, τα οποια διαθετουν δραστηριοτητα φρουκτοζυλικης τρανσφερασης, και η χρηση αυτων
ATE87932T1 (de) Alpha-oligonukleotide.
DE69815370D1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
PT80909B (pt) Processo de preparacao de composicoes- sonda e processo para a deteccao de microrganismos, designadamente legionella, nos meios que os contem
DK0840802T3 (da) Fremgangsmåde til sekvensering gennem oligomerhybridisering
NO970885L (no) Oligonukleotid konjugater, sammensetninger og fremgangsmåter for splitting av ribonukleotider
ATE317123T1 (de) Reaktiver träger zur bestimmung von dna fragmenten
DE69637684D1 (de) Dna moleküle